tradingkey.logo
tradingkey.logo
Search

Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors

ReutersApr 21, 2025 11:49 AM
facebooktwitterlinkedin

- Zai Lab Ltd 9688.HK:

  • ZAI LAB ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR REPOTRECTINIB FOR PATIENTS WITH NTRK-POSITIVE SOLID TUMORS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI